Transplantation of High Panel-Reactive Antibody Left Ventricular Assist Device Patients Without Crossmatch Using On-Bypass Pheresis and Alemtuzumab
Authors:
- Scott D. LickSLScott D. Lick
- Daniel L. BecklesDBDaniel L. Beckles
- Giovanni PiovesanaGPGiovanni Piovesana
- Smita VaidyaSVSmita Vaidya
- Alexander IndrikovsAIAlexander Indrikovs
- N. Alexander BarbagelataN. Alexander Barbagelata
- Vincent ValentineVVVincent Valentine
- 1 October 2011
- journal article
- research article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 92 (4) , 1428-1434
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Management of the sensitized adult heart transplant candidateClinical Transplantation, 2010
- Report From a Consensus Conference on the Sensitized Patient Awaiting Heart TransplantationThe Journal of Heart and Lung Transplantation, 2009
- The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantationTransplant Immunology, 2008
- Cardiac Transplant Outcomes in Pediatric Patients with Pre-formed Anti-Human Leukocyte Antigen Antibodies and/or Positive Retrospective CrossmatchThe Journal of Heart and Lung Transplantation, 2007
- Alemtuzumab (Campath 1H) as Successful Salvage Therapy for Recurrent Steroid-resistant Heart Transplant RejectionThe Journal of Heart and Lung Transplantation, 2007
- 125: Treatment of HLA sensitized pre-transplant patients with mechanical support is effective for PRA reductionThe Journal of Heart and Lung Transplantation, 2007
- Alemtuzumab (Campath-1H): A Systematic Review in Organ TransplantationTransplantation, 2006
- Effect of Campath-1H antibody on human hematopoietic progenitors in vitroBlood, 1993
- The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantationTransplant Immunology, 1993
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990